Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
NCT ID NCT07722494
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether an experimental immunotherapy called IBI363, combined with the anti-angiogenic drug bevacizumab, can help people with advanced colorectal cancer that has stopped responding to standard treatments. About 550 adults whose cancer has progressed or who cannot tolerate current therapies will receive either the combination or one of three standard options (fruquintinib, trifluridine/tipiracil, or regorafenib). The main goal is to see if the new combination improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of IBI363 (an experimental immunotherapy) and bevacizumab (a drug that blocks blood vessel growth to tumors)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced colorectal cancer who have run out of standard options.
- What could go wrong
- This is an early-phase 3 trial, so the combination may not prove more effective than existing therapies and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Wuhan, 430021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can we predict who will survive a bowel surgery leak?
- Can a four-drug cocktail shrink hard-to-treat colorectal cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
- A mobile app aims to turn health awareness into action — a trial puts it to the test